Extended Input Deadline for USP´s new Chapter on Quality Considerations for Cannabis
Recommendation
Thursday, 29 October 2026 9 .00 - 17.15 h
AI/ML-based Methods for Optimizing Pharmaceutical Research Processes
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Following the previously announced elaboration of a new USP chapter <1568> Quality Considerations for Cannabis and Cannabis-derived Products for Clinical Research the input deadline has been extended to 31 July 2022.
USP is requesting early input from stakeholders on the proposed new General Chapter <1568> which is then expected to be published for comment in Pharmacopeial Forum.
More Information is available at the USP Compendial Notices Website.
Related GMP News
29.09.2026FDA wants to Advance the Development of Herbal Medicinal Products
29.09.2026Ph. Eur. Draft for Comment: 2.8.18. Determination of Aflatoxin B1 in Herbal Drugs
29.09.2026Can Cannabis Flowers be pre-dried in Accordance with GACP?
29.09.2026Water Determination in Herbal Drugs
10.09.2026New Information Sheet regarding Cannabis for Medical Purposes
10.09.2026EMA Reflection Paper on Safety Signals for Herbal Medicinal Products